R R

What Is Onureg?

Onureg is a prescription cancer medication containing azacitidine, a nucleoside metabolic inhibitor. It is approved for continued treatment of adults with acute myeloid leukemia (AML) who achieved their first complete remission or complete remission with incomplete blood count recovery after intensive induction chemotherapy and cannot complete intensive curative therapy. Onureg is taken orally in repeating treatment cycles. It helps prolong remission but does not cure AML. Onureg tablets must not be substituted for injectable azacitidine because the formulations have different approved uses and dosing schedules.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Onureg?

Onureg is a prescription cancer medication containing azacitidine, a nucleoside metabolic inhibitor. It is approved for continued treatment of adults with acute myeloid leukemia (AML) who achieved their first complete remission or complete remission with incomplete blood count recovery after intensive induction chemotherapy and cannot complete intensive curative therapy. Onureg is taken orally in repeating treatment cycles. It helps prolong remission but does not cure AML. Onureg tablets must not be substituted for injectable azacitidine because the formulations have different approved uses and dosing schedules.

read more about onureg ...

Copy this HTML:

Copy HTML Copied!

How Does Onureg Work?

Onureg contains azacitidine, which interferes with processes involved in cancer cell growth and survival. Azacitidine can become incorporated into RNA and DNA, altering cellular activity and inhibiting DNA methylation. Changes in DNA methylation can affect gene expression, while incorporation into genetic material contributes to damage in susceptible cells. These actions can help suppress abnormal blood-forming cells associated with AML. Oral azacitidine has different drug exposure characteristics from injectable azacitidine, so the two formulations are not interchangeable.

Who Can Receive Onureg Treatment?

Onureg is approved for adults with AML who have achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and are unable to complete intensive curative therapy. It is used after initial leukemia treatment rather than as a replacement for induction chemotherapy. An oncology specialist reviews blood counts, remission status, previous treatment, and the patient's ability to tolerate further therapy before prescribing it. Onureg is not approved as an equivalent substitute for injectable azacitidine used in other blood disorders.

How Should Onureg Be Taken?

The recommended Onureg dose is 300 mg orally once daily on days one through 14 of each 28-day cycle, with or without food. Tablets should be swallowed whole without crushing, cutting, or chewing. An anti-nausea medication is recommended before each dose during at least the first two treatment cycles. Blood counts are monitored regularly, and treatment can be interrupted or adjusted for significant adverse effects. A missed dose can be taken later on the same day, but two doses should not be taken in one day. Do not repeat a dose after vomiting.

What Are the Side Effects and Warnings of Onureg?

Common adverse effects include nausea, vomiting, diarrhea, fatigue, constipation, and reduced appetite. Serious risks include low blood cell counts, severe infections, febrile neutropenia, and potentially life-threatening complications from myelosuppression. Onureg can also harm an unborn baby. Clinicians monitor blood counts before and during treatment and assess patients for infection and bleeding. Fever, unusual bruising, persistent vomiting, or severe weakness requires prompt medical evaluation. Patients should follow their oncology team's instructions for dose changes and supportive medications.

Common Questions About Onureg

Is Onureg the same as azacitidine?

Onureg contains azacitidine, but its oral formulation is not interchangeable with injectable azacitidine. The formulations have different dosing schedules and approved indications.

Does Onureg treat acute myeloid leukemia?

Yes. Onureg is approved for continued treatment of certain adults with AML who achieved remission after intensive induction chemotherapy and cannot complete intensive curative therapy.

How often is Onureg taken?

Onureg is generally taken once daily for the first 14 days of each 28-day treatment cycle. The standard dose is 300 mg daily unless adjusted by the prescriber.

Can Onureg cause low blood counts?

Yes. Onureg can cause myelosuppression, including reduced neutrophils and platelets. Regular blood testing is necessary to monitor treatment safety.

References

Azacitidine. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548363/. Date Accessed October 22, 2026.

Azacitidine. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620060.html. Date Accessed October 22, 2026.

Azacitidine. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/azacitidine. Date Accessed October 22, 2026.

Azacitidine. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Azacitidine. Date Accessed October 22, 2026.

DailyMed - ONUREG (azacitidine) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e95e33f-8aba-4f19-b332-2416580d358b. Date Accessed October 22, 2026.